Tenderwize
Zurück zur Suche

Open-house rebate agreement for Meropenem

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 05, 2027 · 189 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Meropenem, ATC J01DH02

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

48 / 100

Risikofaktoren

Paper submissions are only treated as timely if the complete and correct originals arrive by the 10th of the month afte...

The buyer states that only pharmaceutical companies are eligible as potential contract partners.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive rebate agreements for the medicinal product Meropenem, ATC J01DH02.
  • Open-house model with identical, pre-set contract terms for all eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical rebate agreement for Meropenem (ATC J01DH02) offered by AOK Bayern. It is not a competitive award procedure: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. No contract value is stated. Submission is possible electronically via DTVP with a qualified electronic signature or in paper form in duplicate originals. The deadline for receipt of complete and correct documents is 2027-03-05 11:00, with monthly contract start mechanics described in the notice.

Risiken

Paper submissions are only treated as timely if the complete and correct originals arrive by the 10th of the month afte...

The buyer states that only pharmaceutical companies are eligible as potential contract partners.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability/suitability must be submitted.
  • The signed contract and the completed annex 'Determination of the medicinal products covered by the contract' must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Meropenem

Single lot for non-exclusive open-house rebate agreements for the pharmaceutical product Meropenem, ATC J01DH02. The notice says the contract terms are identical and not individually negotiable. Performance is in Germany, specifically Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Apr 2025 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Mar 05, 2027

Vergabedetails

Veröffentlichungsdatum
18 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
176004-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30